title: Lack of evidence that cyclosporine treatment impairs calcium-phosphorus homeostasis and bone remodeling in normocalcemic long-term renal transplant recipients.
abstract: Since the effects of cyclosporine on mineral and bone metabolism are controversial, we studied calcium regulating hormones, calcium-phosphorus (Ca-P) metabolism, and bone remodeling, assessed by serum osteocalcin, in long-term renal transplant recipients (RT). Forty-seven normocalcemic patients with good renal function receiving cyclosporine (CT, n = 27) or not (NC, n = 20) were studied at baseline and after an oral Ca load. CT and NC had similar age, daily dose of steroids, GFR level, and duration of transplantation. Baseline evaluation included 24-hr urinary Ca, P, TRP, TmP/GFR, fasting serum intact PTH, 1,25-(OH)2D, 25OHD, osteocalcin, Ca, and P. Subjects of the two groups had excessive secretion of PTH, tubular P wasting, and high serum osteocalcin level, as is usual in RT. However, there was no difference between CT and NC regarding any baseline variable. Ten CT and ten NC, matched for duration of transplantation and serum PTH level, ingested 1g Ca to achieve an acute dynamic study of PTH secretion and Ca-P metabolism. In both CT and NC, this Ca load caused the same decreases in serum PTH (P < 0.001), NcAMP (P < 0.05), and urinary P (P < 0.001) and the same increases in serum and urinary Ca (P < 0.001), and in both TmP/GFR and TRP (P < 0.001). These results strongly suggest that cyclosporine treatment had no significant effect on calcium-regulating hormone secretion, P-Ca metabolism, and bone remodeling level. We therefore consider that cyclosporine is unlikely to have any prominent role in the abnormalities of bone endocrine and mineral metabolism that are common in long-term kidney recipients.
authors.affiliation: Explorations Fonctionnelles Rénales Métaboliques et Endocriniennes, Centre Hospitalier Universitaire, Besançon, France.
authors.forename: G
authors.initials: G
authors.lastname: Dumoulin
authors.forename: B
authors.initials: B
authors.lastname: Hory
authors.forename: N U
authors.initials: NU
authors.lastname: Nguyen
authors.forename: M T
authors.initials: MT
authors.lastname: Henriet
authors.forename: C
authors.initials: C
authors.lastname: Bresson
authors.forename: J
authors.initials: J
authors.lastname: Regnard
authors.forename: Y
authors.initials: Y
authors.lastname: Saint-Hillier
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D016723:Bone Remodeling / Q000187:drug effects*; D002118:Calcium / Q000008:administration & dosage / Q000097:blood / Q000378:metabolism*; D016572:Cyclosporine / Q000009:adverse effects*; D004100:Dihydroxycholecalciferols / Q000097:blood; D005260:Female; D006706:Homeostasis / Q000187:drug effects*; D006801:Humans; D007668:Kidney / Q000502:physiology; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D015675:Osteocalcin / Q000097:blood; D010280:Parathyroid Glands / Q000187:drug effects / Q000502:physiology; D010281:Parathyroid Hormone / Q000097:blood; D010758:Phosphorus / Q000097:blood / Q000378:metabolism* / Q000652:urine; D013997:Time Factors
chemical_list: D004100:Dihydroxycholecalciferols; D010281:Parathyroid Hormone; D015675:Osteocalcin; D010758:Phosphorus; D016572:Cyclosporine; D002118:Calcium